Understanding the origin of non-immune cellmediated weakness in the idiopathic inflammatory myopathies - Potential role of ER stress pathways

Current Opinion in Rheumatology

Volumn 27, Issue 6, 2015, Pages 580-585

  Lightfoot, Adam P ^a   Nagaraju, Kanneboyina ^b,c   McArdle, Anne ^a   Cooper, Robert G ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Endoplasmic reticulum stress; Idiopathic inflammatory myopathies; Mitochondria; Myokine; Myositis; Reactive oxygen species; Skeletal muscle; Weakness

Indexed keywords

CYTOKINE; REACTIVE OXYGEN METABOLITE;

ARTICLE; CELL FUNCTION; CELL INFILTRATION; DISEASE ACTIVITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; HUMAN; INFLAMMATORY CELL; MITOCHONDRION; MUSCLE FUNCTION; MUSCLE WEAKNESS; MYOSITIS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; ANIMAL; BIOSYNTHESIS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CYTOKINES; ENDOPLASMIC RETICULUM STRESS; HUMANS; MITOCHONDRIAL DISEASES; MUSCLE WEAKNESS; MYOSITIS; REACTIVE OXYGEN SPECIES;

EID: 84942514463     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000212     Document Type: Article

References (59)

1. Mastaglia FL, Phillips BA. Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am 2002; 28:723-741.
2. Betteridge ZE, Gunawardena H, McHugh NJ. Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res Ther 2011; 13:209.
3. Lega JC, Fabien N, Reynaud Q, et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimm Rev 2014; 13:883-891.
4. Madan V, Chinoy H, Griffiths CE, Cooper RG. Defining cancer risk in dermatomyositis. Part I. Clin Exp Dermatol 2009; 34:451-455.
5. Madan V, Chinoy H, Griffiths CE, Cooper RG. Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology. Clin Exp Dermatol 2009; 34:561-565.
6. Lokesh S, Kadvanu T, Raghupathy SV, Balekrishna M. A Rare Case of Mixed Connective Tissue Disease (MCTD) with intricate features of lupus, polymyositis and rheumatoid arthritis presenting with severe myositis. J Clin Diagn Res 2015; 9:OD05-OD07.
7. Venalis P, Lundberg IE. Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Rheumatology (Oxford) 2014; 53:397-405.
8. Englund P, Lindroos E, Nennesmo I, et al. Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies. Am J Pathol 2001; 159:1263-1273.
9. Coley W, Rayavarapu S, Pandey GS, et al. The molecular basis of skeletal muscle weakness in a mouse model of inflammatory myopathy. Arthritis Rheum 2012; 64:3750-3759.
10. Coley W, Rayavarapu S, Nagaraju K. Role of nonimmune mechanisms of muscle damage in idiopathic inflammatory myopathies. Arthritis Res Ther 2012; 14:209.
11. Lightfoot AP, McArdle A, Jackson MJ, Cooper RG. In the idiopathic inflammatory myopathies (IIM), do reactive oxygen species (ROS) contribute to muscle weakness? Ann Rheum Dis 2015; 74:1340-1346.
12. Ibrahim F, Choy E, Gordon P, et al. Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids. Rheumatology (Oxford) 2015; 54:1050-1055.
13. Nagaraju K, Casciola-Rosen L, Lundberg I, et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 2005; 52:1824-1835.
14. Rossi AE, Dirksen RT. Sarcoplasmic reticulum: the dynamic calcium governor of muscle. Muscle Nerve 2006; 33:715-731.
15. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science 2011; 334:1081-1086.
16. Hebert DN, Molinari M. In and out of the ER: protein folding, quality control, degradation, and related human diseases. Physiol Rev 2007; 87:1377-1408.
17. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010; 140:900-917.
18. Li CK, Knopp P, Moncrieffe H, et al. Overexpression of MHC class I heavy chain protein in young skeletal muscle leads to severe myositis: implications for juvenile myositis. Am J Pathol 2009; 175:1030-1040.
19. Vitadello M, Doria A, Tarricone E, et al. Myofiber stress-response in myositis: parallel investigations on patients and experimental animal models of muscle regeneration and systemic inflammation. Arthritis Res Ther 2010; 12:R52.
20. Freret M, Drouot L, Obry A, et al. Overexpression of MHC class I in muscle of lymphocyte-deficient mice causes a severe myopathy with induction of the unfolded protein response. Am J Pathol 2013; 183:893-904.
21. Powers SK, Ji LL, Kavazis AN, Jackson MJ. Reactive oxygen species: impact on skeletal muscle. Compr Physiol 2011; 1:941-969.
22. Flohe L, Brigelius-Flohe R, Saliou C, et al. Redox regulation of NF-kappa B activation. Free Radic Biol Med 1997; 22:1115-1126.
23. Terrill JR, Radley-Crabb HG, Iwasaki T, et al. Oxidative stress and pathology in muscular dystrophies: focus on protein thiol oxidation and dysferlinopathies. FEBS J 2013; 280:4149-4164.
24. Lightfoot AP, McCormick R, Nye GA, McArdle A. Mechanisms of skeletal muscle ageing; avenues for therapeutic intervention. Curr Opin Pharmacol 2014; 16:116-121.
25. Vasilaki A, Mansouri A, Remmen H, et al. Free radical generation by skeletal muscle of adult and old mice: effect of contractile activity. Aging Cell 2006; 5:109-117.
26. Lawler JM. Exacerbation of pathology by oxidative stress in respiratory and locomotor muscles with Duchenne muscular dystrophy. J Physiol 2011; 589 (Pt 9):2161-2170.
27. Dhanarajan RPAB, Alexander M, Chacko G, Oommen A. Degradation of myofibrillar proteins and inadequate antioxidants in selective muscle wasting of limb girdle muscular dystrophy. Int J Case Reports Images 2011; 2:6-11.
28. Siegel MP, Kruse SE, Percival JM, et al. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell 2013; 12:763-771.
29. Whitehead NP, Pham C, Gervasio OL, Allen DG. N-Acetylcysteine ameliorates skeletal muscle pathophysiology in mdx mice. J Physiol 2008; 586:2003-2014.
30. Tews DS, Goebel HH. Cell death and oxidative damage in inflammatory myopathies. Clin Immunol Immunopathol 1998; 87:240-247.
31. Rudolf R, Mongillo M, Magalhaes PJ, Pozzan T. In vivo monitoring of Ca(2+) uptake into mitochondria of mouse skeletal muscle during contraction. J Cell Biol 2004; 166:527-536.
32. Kaufman RJ, Malhotra JD. Calcium trafficking integrates endoplasmic reticulum function with mitochondrial bioenergetics. Biochim Biophys Acta 2014; 1843:2233-2239.
33. Bravo R, Vicencio JM, Parra V, et al. Increased ER-mitochondrial coupling promotes mitochondrial respiration and bioenergetics during early phases of ER stress. J Cell Sci 2011; 124 (Pt 13):2143-2152.
34. Yamada T, Mishima T, Sakamoto M, et al. Myofibrillar protein oxidation and contractile dysfunction in hyperthyroid rat diaphragm. J Appl Physiol (1985) 2007; 102:1850-1855.
35. Win S, Than TA, Fernandez-Checa JC, Kaplowitz N. JNK interaction with Sab mediates ER stress induced inhibition of mitochondrial respiration and cell death. Cell death & disease 2014; 5:e989.
36. Toime LJ, Brand MD. Uncoupling protein-3 lowers reactive oxygen species production in isolated mitochondria. Free Radic Biol Med 2010; 49:606-611.
37. Rygiel KA, Miller J, Grady JP, et al. Mitochondrial and inflammatory changes in sporadic inclusion body myositis. Neuropathol Appl Neurobiol 2015; 41:288-303.
38. Miquel E, Cassina A, Martinez-Palma L, et al. Neuroprotective effects of the mitochondria-targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosis. Free Radic Biol Med 2014; 70:204-213.
39. Pirinen E, Canto C, Jo YS, et al. Pharmacological Inhibition of poly(ADPribose) polymerases improves fitness and mitochondrial function in skeletal muscle. Cell metabolism 2014; 19:1034-1041.
40. Das S, Morvan F, Jourde B, et al. ATP citrate lyase improves mitochondrial function in skeletal muscle. Cell Metab 2015; 21:868-876.
41. Varanita T, Soriano ME, Romanello V, et al. The opa1-dependent mitochondrial cristae remodeling pathway controls atrophic, apoptotic, and ischemic tissue damage. Cell Metab 2015; 21:834-844.
42. Civiletto G, Varanita T, Cerutti R, et al. Opa1 overexpression ameliorates the phenotype of two mitochondrial disease mouse models. Cell Metab 2015; 21:845-854.
43. Nagaraju K, Raben N, Merritt G, et al. A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli. Clin Exp Immunol 1998; 113:407-414.
44. Lightfoot A, McArdle A, Griffiths RD. Muscle in defense. Crit Care Med 2009; 37 (10 Suppl):S384-S390.
45. Benatti FB, Pedersen BK. Exercise as an anti-inflammatory therapy for rheumatic diseases-myokine regulation. Nat Revi Rheum 2015; 11:86-97.
46. Cox TR, Rumney RM, Schoof EM, et al. The hypoxic cancer secretome induces premetastatic bone lesions through lysyl oxidase. Nature 2015; 522:106-110.
47. Salomonsson S, Lundberg IE. Cytokines in idiopathic inflammatory myopathies. Autoimmunity 2006; 39:177-190.
48. Civatte M, Bartoli C, Schleinitz N, et al. Expression of the beta chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 2005; 31:70-79.
49. Zong M, Loell I, Lindroos E, et al. Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor alpha expression in muscle tissue of patients with polymyositis or dermatomyositis. Ann Rheum Dis 2012; 71:1055-1063.
50. Hartwig S, Raschke S, Knebel B, et al. Secretome profiling of primary human skeletal muscle cells. Biochim Biophys Acta 2014; 1844:1011-1017.
51. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on musclederived interleukin-6. Physiol Rev 2008; 88:1379-1406.
52. Steensberg A, Fischer CP, Keller C, et al. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab 2003; 285:E433-E437.
53. Alexanderson H. Exercise in inflammatory myopathies, including inclusion body myositis. Curr Rheumatol Rep 2012; 14:244-251.
54. Welc SS, Judge AR, Clanton TL. Skeletal muscle interleukin-6 regulation in hyperthermia. Am J Physiol Cell Physiol 2013; 305:C406-C413.
55. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999; 18:6853-6866.
56. Cai D, Frantz JD, Tawa NE Jr, et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 2004; 119:285-298.
57. Lightfoot AP, Goljanek-Whysall K, Earl KE, et al. Is Muscle a Chemotactic Organ in the Idiopathic Inflammatory Myopathies (IIM)? Overexpression of MHC I (H-2Kb) in C2C12 Myotubes Results in Release of Pro-Inflammatory Cytokines. Rheumatology (Oxford) 2015; 54 (Supp 1):i43. doi: 10.1093/rheumatology/kev085.006.
58. Haddad F, Zaldivar F, Cooper DM, Adams GR. IL-6-induced skeletal muscle atrophy. J Appl Physiol 2005; 98:911-917.
59. Reid MB, Moylan JS. Beyond atrophy: redox mechanisms of muscle dysfunction in chronic inflammatory disease. J Physiol 2011; 589 (Pt 9):2171-2179.